Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling

Trends in Biochemical Sciences

Volumn 36, Issue 9, 2011, Pages 457-469

  Shukla, Arun K ^a   Xiao, Kunhong ^a   Lefkowitz, Robert J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; BETA ARRESTIN 1; BETA ARRESTIN 4; CHEMOKINE RECEPTOR CXCR4; CONE ARRESTIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 3; G PROTEIN COUPLED RECEPTOR KINASE 5; G PROTEIN COUPLED RECEPTOR KINASE 6; G PROTEIN COUPLED RECEPTOR KINASE 7; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; JANUS KINASE 2; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINIC ACID RECEPTOR; PHOSPHOPROTEIN; RETINA S ANTIGEN; RHODOPSIN KINASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 4; X ARRESTIN;

CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; ENDOCYTOSIS; HOMODIMERIZATION; HUMAN; INTERNALIZATION; INTRACELLULAR SIGNALING; NUCLEAR LOCALIZATION SIGNAL; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR DOWN REGULATION; REVIEW; SYSTEMS BIOLOGY; UBIQUITINATION;

ANGIOTENSIN II; ANIMALS; ARRESTINS; ENDOCYTOSIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MEMBRANE PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN TRANSPORT; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; UBIQUITINATION;

EID: 80052359992     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2011.06.003     Document Type: Review

References (97)

1. Bjarnadottir T.K., et al. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 2006, 88:263-273.
2. Bockaert J., Pin J.P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 1999, 18:1723-1729.
3. Pierce K.L., et al. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 2002, 3:639-650.
4. Ma P., Zemmel R. Value of novelty?. Nat. Rev. Drug Discov. 2002, 1:571-572.
5. Birnbaumer L. The discovery of signal transduction by G proteins: a personal account and an overview of the initial findings and contributions that led to our present understanding. Biochim. Biophys. Acta 2007, 1768:756-771.
6. Birnbaumer L., et al. G protein coupling of receptors to ionic channels and other effector systems. Soc. Gen. Physiol. Ser. 1990, 45:169-183.
7. Benovic J.L., et al. Beta-adrenergic receptor kinase: primary structure delineates a multigene family. Science 1989, 246:235-240.
8. Pitcher J.A., et al. Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases. J. Biol. Chem. 1999, 274:34531-34534.
9. Penela P., et al. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal. 2003, 15:973-981.
10. Stoffel R.H., et al. Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid modification diversity in the GRK family. J. Biol. Chem. 1994, 269:27791-27794.
11. Lefkowitz R.J., et al. Role of phosphorylation in desensitization of the beta-adrenoceptor. Trends Pharmacol. Sci. 1990, 11:190-194.
12. Torrecilla I., et al. Phosphorylation and regulation of a G protein-coupled receptor by protein kinase CK2. J. Cell. Biol. 2007, 177:127-137.
13. Strachan R.T., et al. Ribosomal S6 kinase 2 directly phosphorylates the 5-hydroxytryptamine 2A (5-HT2A) serotonin receptor, thereby modulating 5-HT2A signaling. J. Biol. Chem. 2009, 284:5557-5573.
14. Lefkowitz R.J. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J. Biol. Chem. 1998, 273:18677-18680.
15. Attramadal H., et al. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J. Biol. Chem. 1992, 267:17882-17890.
16. Hirsch J.A., et al. The 2.8 A crystal structure of visual arrestin: a model for arrestin's regulation. Cell 1999, 97:257-269.
17. Han M., et al. Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane Translocation. Structure 2001, 9:869-880.
18. Zhan X., et al. Crystal structure of arrestin-3 reveals the basis of the difference in receptor binding between two non-visual subtypes. J. Mol. Biol. 2011, 406:467-478.
19. McDonald P.H., Lefkowitz R.J. beta-Arrestins: new roles in regulating heptahelical receptors' functions. Cell Signal. 2001, 13:683-689.
20. Goodman O.B., et al. beta-Arrestin acts as a clathrin adaptor in endocytosis of the beta(2)-adrenergic receptor. Nature 1996, 383:447-450.
21. Laporte S.A., et al. The beta2-adrenergic receptor/beta-arrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3712-3717.
22. Claing A., et al. beta-Arrestin-mediated ADP-ribosylation factor 6 activation and beta 2-adrenergic receptor endocytosis. J. Biol. Chem. 2001, 276:42509-42513.
23. McDonald P.H., et al. Identification of NSF as a beta-arrestin1-binding protein - implications for beta(2)-adrenergic receptor regulation. J. Biol. Chem. 1999, 274:10677-10680.
24. Fraile-Ramos A., Marsh M. Endocytosis of the viral chemokine receptor US28 does not require beta-arrestins. Mol. Biol. Cell 2002, 13:365a.
25. Oakley R.H., et al. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 2000, 275:17201-17210.
26. Oakley R.H., et al. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J. Biol. Chem. 1999, 274:32248-32257.
27. Shenoy S.K. Seven-transmembrane receptors and ubiquitination. Circ. Res. 2007, 100:1142-1154.
28. Shenoy S.K., et al. Regulation of receptor fate by ubiquitination of activated beta(2)-adrenergic receptor and beta-arrestin. Science 2001, 294:1307-1313.
29. Shenoy S.K., et al. Nedd4 mediates agonist-dependent ubiquitination, lysosomal targeting, and degradation of the beta(2)-adrenergic receptor. J. Biol. Chem. 2008, 283:22166-22176.
30. Marchese A., et al. The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Dev. Cell 2003, 5:709-722.
31. Chen W., et al. beta-Arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science 2003, 301:1394-1397.
32. Girnita L., et al. beta-Arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J. Biol. Chem. 2007, 282:11329-11338.
33. Puckerin A., et al. Arrestin is required for agonist-induced trafficking of voltage-dependent calcium channels. J. Biol. Chem. 2006, 281:31131-31141.
34. Lipsky R., et al. beta-Adrenergic receptor activation induces internalization of cardiac Cav1.2 channel complexes through a beta-Arrestin 1-mediated pathway. J. Biol. Chem. 2008, 283:17221-17226.
35. Shukla A.K., et al. Arresting a transient receptor potential (TRP) channel beta-arrestin 1 mediates ubiquitination and functional down-regulation of TRPV4. J. Biol. Chem. 2010, 285:30115-30125.
36. Simonin A., Fuster D. Nedd4-1 and beta-arrestin-1 are key regulators of Na+/H+exchanger 1 ubiquitylation, endocytosis, and function. J. Biol. Chem. 2010, 285:38293-38303.
37. Szabo E.Z., et al. beta-Arrestins bind and decrease cell-surface abundance of the Na+/H+exchanger NHE5 isoform. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2790-2795.
38. Lakshmikanthan V., et al. Identification of beta Arrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9379-9384.
39. Gavard J., Gutkind J.S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol. 2006, 8:1223-1234.
40. Mukherjee A., et al. Regulation of Notch signalling by non-visual beta-arrestin. Nat. Cell Biol. 2005, 7:1191-1201.
41. Lin C.H., et al. Arrestin-related ubiquitin-ligase adaptors regulate endocytosis and protein turnover at the cell surface. Cell 2008, 135:714-725.
42. Nikko E., Pelham H.R.B. Arrestin-mediated endocytosis of yeast plasma membrane transporters. Traffic 2009, 10:1856-1867.
43. Nikko E., et al. Arrestin-like proteins mediate ubiquitination and endocytosis of the yeast metal transporter Smf1. EMBO Rep. 2008, 9:1216-1221.
44. Luttrell L.M., et al. beta-Arrestin-dependent formation of beta(2) adrenergic receptor Src protein kinase complexes. Science 1999, 283:655-661.
45. Leftowitz R.J., Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 2005, 308:512-517.
46. Imamura T., et al. beta-Arrestin-mediated recruitment of the Src family kinase yes mediates endothelin-1-stimulated glucose transport. J. Biol. Chem. 2001, 276:43663-43667.
47. Gong K.Z., et al. A novel protein kinase A-independent, beta-arrestin-1-dependent signaling pathway for p38 mitogen-activated protein kinase activation by beta(2)-adrenergic receptors. J. Biol. Chem. 2008, 283:29028-29036.
48. McDonald P.H., et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 2000, 290:1574-1577.
49. Beaulieu J.M., et al. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
50. Povsic T.J., et al. Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J. Biol. Chem. 2003, 278:51334-51339.
51. Schmid C.L., Bohn L.M. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ss-arrestin2/Src/Akt signaling complex in vivo. J. Neurosci. 2010, 30:13513-13524.
52. Naga Prasad S.V., et al. Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J. Cell Biol. 2002, 158:563-575.
53. Wang P., DeFea K.A. Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent inhibition and Galphaq-dependent activation of phosphatidylinositol 3-kinase. Biochemistry 2006, 45:9374-9385.
54. Cheung R., et al. An arrestin-dependent multi-kinase signaling complex mediates MIP-1beta/CCL4 signaling and chemotaxis of primary human macrophages. J. Leukoc. Biol. 2009, 86:833-845.
55. Bjorgo E., et al. Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase A signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex. Mol. Cell. Biol. 2010, 30:1660-1672.
56. Li X., et al. Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5. J. Biol. Chem. 2009, 284:16170-16182.
57. DeWire S.M., et al. beta-Arrestins and cell signaling. Annu. Rev. Physiol. 2007, 69:483-510.
58. Violin J.D., Lefkowitz R.J. beta-Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 2007, 28:416-422.
59. Whalen E.J., et al. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17:126-139.
60. Walters R.W., et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J. Clin. Invest. 2009, 119:1312-1321.
61. Semple G., et al. 3-(1H-tetrazol-5-yl)-1, 4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J. Med. Chem. 2008, 51:5101-5108.
62. Violin J.D., et al. TRV120027, a beta-arrestin biased ligand at the angiotensin II type 1 receptor, produces unique pharmacology and is a novel potential therapy for heart failure. J. Cardiac. Fail. 2010, 16:S72.
63. Zidar D.A., et al. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9649-9654.
64. Woo A.Y., et al. Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol. Pharmacol. 2009, 75:158-165.
65. Marrero M.B., et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995, 375:247-250.
66. Butcher A.J., et al. Differential G-protein coupled receptor phosphorylation provides evidence for a signalling barcode. J. Biol. Chem. 2010, 286:11506-11518.
67. Xiao K., et al. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12011-12016.
68. Hunter T. Protein-kinases and phosphatases-the yin and yang of protein-phosphorylation and signaling. Cell 1995, 80:225-236.
69. Pawson T., Scott J.D. Protein phosphorylation in signaling-50 years and counting. Trends Biochem. Sci. 2005, 30:286-290.
70. Xiao K.H., et al. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15299-15304.
71. Christensen G.L., et al. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol. Cell. Proteomics 2010, 9:1540-1553.
72. Bohn L.M., et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999, 286:2495-2498.
73. Kovacs J.J., et al. beta-Arrestin-mediated localization of smoothened to the primary cilium. Science 2008, 320:1777-1781.
74. Shukla A.K., et al. Arresting a transient receptor potential (TRP) channel: beta-arrestin 1 mediates ubiquitination and functional down-regulation of TRPV4. J. Biol. Chem. 2010, 285:30115-30125.
75. Zoudilova M., et al. Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. J. Biol. Chem. 2007, 282:20634-20646.
76. Kang J., et al. A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 2005, 123:833-847.
77. Scott M.G., et al. Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J. Biol. Chem. 2002, 277:37693-37701.
78. Storez H., et al. Homo- and hetero-oligomerization of beta-arrestins in living cells. J. Biol. Chem. 2005, 280:40210-40215.
79. Boularan C., et al. beta-Arrestin 2 oligomerization controls the Mdm2-dependent inhibition of p53. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:18061-18066.
80. Milano S.K., et al. Nonvisual arrestin oligomerization and cellular localization are regulated by inositol hexakisphosphate binding. J. Biol. Chem. 2006, 281:9812-9823.
81. Xu T.R., et al. Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs. Biochem. J. 2008, 413:51-60.
82. Shenoy S.K., Lefkowitz R.J. Receptor-specific ubiquitination of beta-arrestin directs assembly and targeting of seven-transmembrane receptor signalosomes. J. Biol. Chem. 2005, 280:15315-15324.
83. Yao X., et al. Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat. Chem. Biol. 2006, 2:417-422.
84. Reiner S., et al. Differential signaling of the endogenous agonists at the beta(2)-adrenergic receptor. J. Biol. Chem. 2010, 285:36188-36198.
85. Shenoy S.K., et al. beta-Arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J. Biol. Chem. 2006, 281:1261-1273.
86. Wei H., et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10782-10787.
87. Rasmussen S.G., et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011, 469:175-180.
88. Kim J., et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1442-1447.
89. Ren X.R., et al. Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1448-1453.
90. Busillo J.M., Benovic J.L. Regulation of CXCR4 signaling. Biochim. Biophys. Acta 2007, 1768:952-963.
91. Nobles K.N., et al. The active conformation of beta-arrestin1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of beta-arrestins1 and -2. J. Biol. Chem. 2007, 282:21370-21381.
92. Xiao K., et al. Activation-dependent conformational changes in {beta}-arrestin 2. J. Biol. Chem. 2004, 279:55744-55753.
93. Palczewski K., et al. Role of the carboxyl-terminal region of arrestin in binding to phosphorylated rhodopsin. J. Biol. Chem. 1991, 266:15334-15339.
94. Charest P.G., et al. Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep. 2005, 6:334-340.
95. Shukla A.K., et al. Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9988-9993.
96. Rakesh K., et al. beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci. Signal. 2010, 3:ra46.
97. Coureuil M., et al. Meningococcus hijacks a beta2-adrenoceptor/beta-arrestin pathway to cross brain microvasculature endothelium. Cell 2010, 143:1149-1160.